Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action - 22/03/24
, Xue Yang d, ⁎, 1 Abstract |
Alzheimer's disease (AD), characterized by cognitive dysfunction and other behavioral abnormalities, is a progressive neurodegenerative disease that occurs due to aging. Currently, effective drugs to mitigate or treat AD remain unavailable. AD is associated with several abnormalities in neuronal energy metabolism, such as decreased glucose uptake, mitochondrial dysfunction, and defects in cholesterol metabolism. Amp-activated protein kinase (AMPK) is an important serine/threonine protein kinase that regulates the energy status of cells. AMPK is widely present in eukaryotic cells and can sense and regulate energy metabolism to maintain energy supply and demand balance, making it a promising target for energy metabolism-based AD therapy. Therefore, this review aimed to discuss the molecular mechanism of AMPK in the pathogenesis of AD to provide a theoretical basis for the development of new anti-AD drugs. To review the mechanisms of phytochemicals in the treatment of AD via AMPK pathway regulation, we searched PubMed, Google Scholar, Web of Science, and Embase databases using specific keywords related to AD and phytochemicals in September 2023. Phytochemicals can activate AMPK or regulate the AMPK pathway to exert therapeutic effects in AD. The anti-AD mechanisms of these phytochemicals include inhibiting Aβ aggregation, preventing Tau hyperphosphorylation, inhibiting inflammatory response and glial activation, promoting autophagy, and suppressing anti-oxidative stress. Additionally, several AMPK-related pathways are involved in the anti-AD mechanism, including the AMPK/CaMKKβ/mTOR, AMPK/SIRT1/PGC-1α, AMPK/NF-κB/NLRP3, AMPK/mTOR, and PERK/eIF2α pathways. Notably, urolithin A, artemisinin, justicidin A, berberine, stigmasterol, arctigenin, and rutaecarpine are promising AMPK agonists with anti-AD effects. Several phytochemicals are effective AMPK agonists and may have potential applications in AD treatment. Overall, phytochemical-based drugs may overcome the barriers to the effective treatment of neurodegenerative diseases.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | The pathogenesis of Alzheimer’s disease (AD) is closely associated with AMP-activated protein kinase (AMPK) signaling. |
• | 18 studies of phytochemicals regulating AMPK in the treatment of AD were reviewed. |
• | Phytochemicals act as AMPK agonists provided novel multi-mechanistic anti-AD therapeutic strategy. |
Abbreviations : AAK-2, Aβ, ACT, AD, AdipoR1, ADP, AG, AGE, AICAR, AMP, AMPK, AMPKK, APN, ARK5, ATP, AVN C, BACE 1, BBB, BCR, CAMP, CAMKK2, CBS, COX-2, CREB, CRTC, CRH-1, DHM, GLP-1, GLUT3, GSH, GSK3, HO-1, IDE, IGF, IL, IRS, LKB1, LPS, MAPKs, MARK4, MDA, MO25, MTOR, NAD, NF-κB, NFTs, NQO1, Nrf2, PGC-1, PP2A, PP2C-α, Ppm1E, Os-pep, ROS, Rut, SAPP, Sirtuin 1, SOD, SREBP2, STRAD, T2DM, TAB1, TAK 1, TFEB, TGF-β, Thr172, TLR, TNF-α, TSG
Keywords : Phytochemicals, aging, Alzheimer's disease, AMPK, medicinal plants
Plan
Vol 173
Article 116373- avril 2024 Retour au numéro
Article précédent
- Progression of unfolded protein response and ferroptosis in angiogenesis
- Bisha He, Yibao Hu, Qian Cao, Yue Li, Yun Tang, Ting Cao, Xiangping Zhou, Shuangquan Liu
- Glycogen synthase kinase-3: A potential immunotherapeutic target in tumor microenvironment
- Jingyi Liang, Meng Yu, Yunong Li, Lin Zhao, Qian Wei
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?